 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 4 | 1/1 | 返回列表 |
| 查看: 1082 | 回復(fù): 3 | |||
zlwcw木蟲 (著名寫手)
|
[交流]
ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 已有1人參與
|
|
ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2011-10-24 20:00 -------------------------------------------------------------------------------- SHANGHAI, October 24, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"  , a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has, through its main Chinese subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner", acquired the assets in Charles River Laboratories International, Inc.'s ("Charles River" Shanghai research facility. As part of the transaction, ShangPharma will take over Charles River's lease for the facility, which will provide the Company with an additional 2,972 square meters (31,990 square feet) of in-vivo research facilities originally designed for GLP Tox studies, and 1,290 square meters (13,885 square feet) of lab and office space. "The acquisition of one of the best designed and constructed state-of-the-art research facilities and laboratories in China is a major step forward for ShangPharma's in-vivo pharmacology services, which we expect to be a significant revenue growth driver going forward, along with biologics; research manufacturing; and integrated discovery and development services," Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented. "The added world-class research capacity should enable ShangPharma to become a top global player in the area of comprehensive in-vivo pharmacology services with specialized capabilities." Kevin Chen, ShangPharma's President and Chief Operating Officer, commented, "This transaction nearly triples ShangPharma's overall research model production and research capacity, positioning us to further leverage China's advantages in the area of in-vivo studies. The location of this facility within ShangPharma's main research campus is a notable strategic advantage, helping us to achieve significant operating efficiencies through consolidation with our current facilities." "This acquisition from Charles River should support accelerated growth in ShangPharma's biology, preclinical development and biologics services for the next several years," added William Dai, ShangPharma's Chief Financial Officer. "ShangPharma's strong cash position has enabled us to make this strategic investment, which we expect will provide excellent returns and maximize shareholder value." Financial terms of the deal, which is subject to customary closing conditions, were not announced. ABOUT SHANGPHARMA CORPORATION ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. For further information, please contact: ShangPharma Ms. Lan Xie VP of Finance and Investor Relations Email: ir@shangpharma.com Brunswick Group Josh Gartner Email: shangpharma@brunswickgroup.com Phone: 86-10-5960-8600 |
回復(fù)此樓» 猜你喜歡
見刊快的中文核心期刊
已經(jīng)有2人回復(fù)
-
一志愿天中醫(yī)中藥學(xué)專碩，希望有b區(qū)的老師可以考慮一下我
已經(jīng)有1人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有186人回復(fù)
-
調(diào)劑
已經(jīng)有3人回復(fù)
-
藥學(xué)學(xué)碩326求調(diào)劑
已經(jīng)有0人回復(fù)
-
26年博士申請
已經(jīng)有20人回復(fù)
-
求助 苯磷硫胺JP
已經(jīng)有0人回復(fù)
-
100金幣 阿莫西林克拉維酸鉀片BP藥典中提到的克拉維酸聚合物具體結(jié)構(gòu)式是啥？
已經(jīng)有2人回復(fù)
-
膳食補(bǔ)充劑合規(guī)性交流
已經(jīng)有0人回復(fù)
-
一志愿浙大藥學(xué)求調(diào)劑
已經(jīng)有0人回復(fù)
-
高溫高壓反應(yīng)求助
已經(jīng)有1人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 鋰電池的兩篇review(Nature and Materials Research Bulletin)
已經(jīng)有286人回復(fù)
- Tier 2 Canada Research Chair in Organic and Medicinal Chemistry 是什么職稱？
已經(jīng)有3人回復(fù)
- PhD Position in Computer Vision from Queen Mary, University of London
已經(jīng)有16人回復(fù)
- Letters in Drug Design & Discovery這個期刊怎么投？
已經(jīng)有15人回復(fù)
- PhD research scholarship in Monash University, Australia
已經(jīng)有25人回復(fù)
- 幫我看看這個“約稿”是不是騙人的？Advances in Materials Research
已經(jīng)有9人回復(fù)
- 【Share】when i fall in love with you
已經(jīng)有58人回復(fù)
- 【招聘】PhD positions in Technical University of Darmstadt, Germany
已經(jīng)有3人回復(fù)
- Environmental Science and Pollution Research
已經(jīng)有14人回復(fù)
1994yw
木蟲 (正式寫手)
- 應(yīng)助: 8 (幼兒園)
- 金幣: 1708.3
- 散金: 105
- 帖子: 646
- 在線: 79.5小時
- 蟲號: 1242523
- 注冊: 2011-03-23
- 專業(yè): 藥物設(shè)計與藥物信息
2樓2011-10-30 15:01:33
zlwcw
木蟲 (著名寫手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 2021.1
- 散金: 225
- 紅花: 8
- 帖子: 1274
- 在線: 219.7小時
- 蟲號: 530429
- 注冊: 2008-03-21
- 性別: GG
- 專業(yè): 代謝性疾病藥物藥理
3樓2011-10-30 17:02:28
1994yw
木蟲 (正式寫手)
- 應(yīng)助: 8 (幼兒園)
- 金幣: 1708.3
- 散金: 105
- 帖子: 646
- 在線: 79.5小時
- 蟲號: 1242523
- 注冊: 2011-03-23
- 專業(yè): 藥物設(shè)計與藥物信息
★
小木蟲(金幣+0.5):給個紅包，謝謝回帖
小木蟲(金幣+0.5):給個紅包，謝謝回帖
|
搞錯了. i美股訊)北京時間10月24日晚消息，尚華醫(yī)藥今天表示，該公司通過旗下子公司——上海睿智化學(xué)研究有限公司公司已收購了CharlES River Laboratories International位于上海的體內(nèi)藥物（In-vivo Drug ）研究室資產(chǎn)。Charles River 是全球領(lǐng)先的研究模式及相關(guān)服務(wù)和臨床前藥物研發(fā)服務(wù)提供商。 作為交易的一部分，尚華醫(yī)藥將接手Charles River對上海研究室的租賃。這起交易完成后，尚華醫(yī)藥將提供額外2，972平方米空間用于GLP Tox研究和1，290 平方米試驗(yàn)和辦公空間。 注冊于開曼群島的尚華醫(yī)藥研發(fā)服務(wù)集團(tuán)是上海睿智化學(xué)研究有限公司、上海凱惠醫(yī)藥化工有限公司及上海開拓者化學(xué)研究管理有限公司的控股公司。 上海睿智化學(xué)研究有限公司成立于2003年4月，公司坐落于中國藥谷——上海市浦東新區(qū)張江高科技園區(qū)生物醫(yī)藥基地內(nèi)。公司目前主要從事為國內(nèi)外客戶提供組合化學(xué)、藥物化學(xué)、合成化學(xué)等領(lǐng)域的科研服務(wù)；化工醫(yī)藥產(chǎn)品質(zhì)量測試；醫(yī)藥生物技術(shù)引進(jìn)、孵化以及成果產(chǎn)業(yè)化等業(yè)務(wù)。睿智化學(xué)擁有8500平方米左右的實(shí)驗(yàn)室。實(shí)驗(yàn)室中均采用世界一流的研究設(shè)備,除具有進(jìn)行有機(jī)合成所必需的先進(jìn)的實(shí)驗(yàn)儀器設(shè)備外，還擁有核磁共振儀,液相色譜-質(zhì)譜聯(lián)用儀,分析型高效液相色譜儀,制備型高效液相色譜儀等先進(jìn)測試儀器。同時，睿智化學(xué)在上海設(shè)立了中試基地，具備精細(xì)化工產(chǎn)品的中試和加工能力。 上海開拓者化學(xué)研究管理有限公司成立于2002年6月，占地12000平方米,位于上海最重要的生物醫(yī)藥研發(fā)基地——張江高科技園區(qū)。 [ Last edited by 1994yw on 2011-10-31 at 21:08 ] |
4樓2011-10-31 21:05:03
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 zlwcw 的主題更新
| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 282求調(diào)劑 +3 | wcq131415 2026-03-24 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 一志愿吉林大學(xué)材料與化工303分求調(diào)劑 +4 | 為學(xué)666 2026-03-24 | 4/200 |
|
|
|
[考研] 299求調(diào)劑 +7 | shxchem 2026-03-20 | 9/450 |
|
|
[考研] 0703化學(xué)求調(diào)劑 +6 | 奶油草莓. 2026-03-22 | 7/350 |
|
|
|
[考研] 求調(diào)劑，一志愿:南京航空航天大學(xué)大學(xué) ，080500材料科學(xué)與工程學(xué)碩，總分289分 +6 | @taotao 2026-03-19 | 6/300 |
|
|
|
[考研] 材料專碩找調(diào)劑 +5 | 哈哈哈吼吼吼哈 2026-03-23 | 5/250 |
|
|
|
[考研] 化工專碩求調(diào)劑 +3 | question挽風(fēng) 2026-03-24 | 3/150 |
|
|
|
[考研] 292求調(diào)劑 +4 | 鵝鵝鵝額額額額?/a> 2026-03-24 | 4/200 |
|
|
|
[考研] 080500求調(diào)劑 +3 | zzzzfan 2026-03-24 | 3/150 |
|
|
|
[考研]
 085404電子信息284分求調(diào)劑
+4
|
13659058978 2026-03-24 | 4/200 |
|
|
|
[考研] 335求調(diào)劑 +4 | yuyu宇 2026-03-23 | 5/250 |
|
|
|
[考研] 327求調(diào)劑 +5 | prayer13 2026-03-23 | 5/250 |
|
|
|
[考研] 接收2026碩士調(diào)劑(學(xué)碩+專碩) +4 | allen-yin 2026-03-23 | 6/300 |
|
|
|
[考研] 333求調(diào)劑 +6 | 87639 2026-03-21 | 10/500 |
|
|
|
[考研] 石河子大學(xué)（211、雙一流）碩博研究生長期招生公告 +3 | 李子目 2026-03-22 | 3/150 |
|
|
|
[考研] 一志愿華中農(nóng)業(yè)071010，總分320求調(diào)劑 +5 | 困困困困坤坤 2026-03-20 | 6/300 |
|
|
|
[考研] 一志愿北京化工大學(xué)070300 學(xué)碩336求調(diào)劑 +5 | vv迷 2026-03-21 | 8/400 |
|
|
|
[考研] 求調(diào)劑 +4 | 要好好無聊 2026-03-21 | 4/200 |
|
|
|
[考研] 一志愿武漢理工材料工程專碩調(diào)劑 +9 | Doleres 2026-03-19 | 9/450 |
|
|
|
[考研] 288求調(diào)劑 +16 | 于海海海海 2026-03-19 | 16/800 |
|